Can the same 4‑mm, 32‑gauge pen needles used for the NovoLog FlexPen be used with the Toujeo (insulin glargine U‑300) pen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, the same 4-mm, 32-gauge pen needles used for NovoLog FlexPen can be used with the Toujeo pen.

Pen needles are universally compatible across insulin pen devices, regardless of insulin type or concentration, as long as they use the standard screw-thread attachment mechanism. Both NovoLog FlexPen and Toujeo pens accept the same pen needles.

Universal Needle Compatibility

The FDA-approved labeling for both products confirms this compatibility:

  • NovoLog FlexPen is designed to be used with NovoFine, NovoFine Plus, or NovoTwist needles 1
  • Toujeo Max SoloStar recommends needles from BD (such as BD Ultra-Fine), Ypsomed (such as Clickfine), or Owen Mumford (such as Unifine Pentips) that are 8 mm long or shorter 2

The key point is that pen needles attach via a universal screw-thread mechanism that fits all major insulin pen brands, including both Novo Nordisk pens (NovoLog) and Sanofi pens (Toujeo).

Optimal Needle Specifications

Current guidelines strongly recommend 4-mm, 32-gauge pen needles for all adults and children with diabetes, regardless of body mass index, insulin type, or pen device 3. This recommendation applies equally to:

  • Rapid-acting insulins (like NovoLog/insulin aspart)
  • Long-acting concentrated insulins (like Toujeo/insulin glargine U-300)

The 4-mm length is:

  • Long enough to reliably deliver insulin to subcutaneous tissue
  • Short enough to avoid intramuscular injection in virtually all patients
  • Associated with less pain than longer needles 3

The 32-gauge width provides optimal balance between:

  • Reduced injection pain (thinner is better)
  • Adequate flow rate for insulin delivery
  • Structural integrity to prevent needle bending or breakage 3

Important Caveats

Never use a syringe to withdraw insulin from Toujeo pens 2. Because Toujeo is U-300 (300 units/mL) versus the standard U-100 concentration, using a U-100 syringe would result in a threefold overdose—a potentially life-threatening error.

Always use a new needle for each injection 3, 1, 2. Needle reuse can cause:

  • Blocked needles leading to underdosing or overdosing
  • Increased infection risk
  • Increased pain
  • Lipohypertrophy (skin thickening/pitting at injection sites)

Injection Technique Considerations

When switching between different insulin types using the same needles:

  • Inject at 90 degrees perpendicular to the skin for most adults using 4-mm needles 3
  • Rotate injection sites within the same anatomic region (abdomen, thigh, buttock, or upper arm) to prevent lipohypertrophy 3, 4
  • Patients with very low BMI (<19 kg/m²) or lean body mass should use a skin lift technique even with 4-mm needles to avoid intramuscular injection 3
  • Allow insulin to reach room temperature before injecting—cold insulin causes more pain 3

The bottom line: Your 4-mm, 32-gauge needles work perfectly for both pens and represent the current gold standard for insulin injection across all insulin types and delivery devices.

Related Questions

How should a 77-year-old patient administer fast-acting insulin aspart (fIASP) alongside insulin glargine 34 units?
In a 71‑year‑old male truck driver with a hemoglobin A1c of 9.7% who is taking insulin glargine (Lantus) 45 units twice daily, glipizide 5 mg before breakfast, and insulin lispro 5 units before each meal, how should his diabetes regimen be adjusted to improve glycemic control and minimize hypoglycemia risk while driving?
In a 77-year-old diabetic patient noncompliant with diet, currently on insulin aspart (Novolog) 35 U at breakfast, 30 U at lunch, and 30 U at dinner, and insulin glargine (Lantus) 45 U in the morning and 50 U at bedtime, with recent hemoglobin A1c of 7.8% and eGFR of 67 mL/min/1.73 m², and fasting and post‑prandial glucose values consistently elevated (fasting 173‑299 mg/dL, pre‑lunch 115‑300 mg/dL, pre‑dinner 148‑239 mg/dL, bedtime 122‑251 mg/dL), should the insulin regimen be adjusted?
With an A1c of 10.6% while taking insulin glargine (Lantus) 42 units twice daily and insulin aspart for meals, how much should the basal insulin dose be increased?
In a 58-year-old patient with diabetes mellitus using insulin glargine (basal) and insulin aspart (prandial), what is the appropriate timing for each insulin dose?
Can metronidazole be used to treat vulvovaginal candidiasis in women?
A patient on sulfamethoxazole/trimethoprim (Bactrim) develops fever, sore throat, nausea, diarrhea, and body aches; what is the appropriate management?
Which insulin‑pen needles (length and gauge) should be used with the insulin aspart (NovoLog) FlexPen?
What is the empiric treatment for uncomplicated vulvovaginal candidiasis in a healthy non‑pregnant woman, and what alternative regimen should be used if she is pregnant?
What are the typical symptoms of shoulder impingement syndrome (rotator cuff tendinopathy)?
Can mycophenolate cause thrombocytopenia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.